Kiora Pharmaceuticals (KPRX) Q2 2024 earnings summary

Executive summary

• Entered a $16M upfront licensing deal for KIO-301 with Théa Open Innovation, with up to $285M in milestones, tiered royalties, and R&D reimbursement; recognized full $16M as Q1 revenue.

• Advanced KIO-301 and KIO-104 toward Phase 2 trials, with finalized trial designs and regulatory engagement for endpoints.

• Achieved EMA Orphan Medicinal Product Designation for KIO-301, positive fMRI data, and grant funding for clinical validation.

• Ended Q2 2024 with $27.8M in cash, cash equivalents, and short-term investments, plus $3.7M in near-term receivables, providing runway into 2027.

• Promoted Melissa Tosca to CFO and appointed Lisa Walters-Hoffert to the Board.

Financial highlights

• Q2 2024 revenue: $20K (grant); six-month revenue: $16.02M, mainly from Théa upfront payment.

• Q2 2024 net loss: $(2.22)M, improved from $(2.6)M in Q2 2023, with six-month net income of $11.23M driven by the Théa deal.

• R&D expenses were $0.9M (net of credits), down from $1.4M year-over-year; G&A expenses rose to $1.5M from $1.1M.

• Cash and cash equivalents at June 30, 2024: $6.6M; short-term investments: $21.2M.

• Ended Q2 with $27.8M in cash and equivalents, $1.3M in collaboration receivables, and $2.3M in R&D tax credits.

Outlook and guidance

• Sufficient liquidity to fund planned operations into 2027 based on current cash, investments, receivables, and tax credits.

• Plans to complete clinical validation and receive approval to initiate Phase 2 ABACUS-2 for KIO-301 in 2H 2024.

• Aims to complete non-clinical Phase 2 enabling work for KIO-104 in 2H 2024 and initiate Phase 2 CLARITY study in 1H 2025.

• Additional financing will be needed for future development and commercialization beyond current pipeline.

• Focus on advancing KIO-301 and KIO-104 clinical programs; seeking partners for KIO-101 and KIO-201.